GBA1 and Parkinson disease: When comparing asymptomatic mutation carriers to carriers of the same mutation at the PD stage, we found a decrease in posterior and anterior basal forebrain volume in PD-GBA1 compared to asymptomatic GBA1 carriers whereas for LRRK2 we found evidence for no difference between asymptomatic mutation carriers and mutation carriers with PD (Table 2).